Form 4: GeneDx Holdings CEO Sells Shares
Insider Transaction (Form 4)
Katherine Stueland, CHIEF EXECUTIVE OFFICER and a Director of GeneDx Holdings Corp., sold 3,692 shares of common stock on September 9, 2026 for $84.22 per share.
Summary
- Option exercise/conversion: acquired 6,547 Class A Common Stock on September 9, 2026; holds 110,919 after (Direct).
- Open-market sale: disposed of 3,692 Class A Common Stock at $84.22 ($310,932) on September 9, 2026; holds 107,227 after (Direct).
- Option exercise/conversion: disposed of 6,547 Restricted Stock Unit on September 9, 2026; holds 6,547 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $310,932 of stock on the open market.
Insider Transactions
Katherine Stueland — Director, Officer (CHIEF EXECUTIVE OFFICER)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-09 | Option exercise/conversion | Class A Common Stock | 6,547 | — | — | 110,919 |
| 2026-09-09 | Open-market sale | Class A Common Stock | 3,692 | $84 | $310.9K | 107,227 |
| 2026-09-09 | Option exercise/conversion | Restricted Stock Unit | 6,547 | — | — | 6,547 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-09 | Option exercise/conversion (6,547 shares) |
| 2026-09-09 | Open-market sale (3,692 shares) |
| 2026-09-09 | Option exercise/conversion (6,547 shares) |
Keywords
insider transaction, Form 4, WGS, GeneDx Holdings Corp., bearish, Katherine Stueland
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.